PMID- 27315045
OWN - NLM
STAT- MEDLINE
DCOM- 20170531
LR  - 20220408
IS  - 1934-6638 (Electronic)
IS  - 1934-662X (Linking)
VI  - 124
IP  - 11
DP  - 2016 Nov
TI  - Estrogen receptor, progesterone receptor, and human epidermal growth factor 
      receptor 2 expression in breast cancer FNA cell blocks and paired histologic 
      specimens: A large retrospective study.
PG  - 828-835
LID - 10.1002/cncy.21745 [doi]
AB  - BACKGROUND: Molecular analysis represents an increasingly important component of 
      the pathologic examination of tumor specimens. Notably, the characterization of 
      estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth 
      factor receptor 2 (HER2) expression in breast cancer specimens provides critical 
      prognostic and predictive information. The objective of the current study was to 
      compare the concordance of these markers as determined on fine-needle aspiration 
      (FNA) cell blocks compared with tissue blocks prepared from surgical specimens. 
      METHODS: A total of 134 cases of breast carcinoma were identified from 2002 
      through 2014 with both FNA cell blocks (fixed in 10% formalin) and corresponding 
      available tissue blocks and ER, PR, and HER2 were characterized in both 
      specimens. Negative and positive concordances were determined for ER and PR in 
      cell blocks compared with tissue blocks, and for HER2 immunohistochemistry on 
      cell blocks and tissue blocks versus the corresponding reference method, 
      fluorescence in situ hybridization (FISH). RESULTS: Concordance for ER expression 
      evaluated on a cell block compared with the corresponding tissue block was 96.2%. 
      Concordance for PR expression was 77.5%. Overall agreement of HER2 FISH testing 
      between cell blocks and tissue blocks was 96.7%. For both cell blocks and tissue 
      blocks, HER2 expression by immunohistochemistry demonstrated >/=98% positive and 
      negative concordance with the FISH reference method. CONCLUSIONS: ER, PR, and 
      HER2 determination on FNA-acquired cell block (fixed exclusively in 10% formalin) 
      showed excellent agreement for ER and HER2 and moderate agreement for PR with the 
      corresponding tissue block. These findings support the equivalency of ER and HER2 
      evaluation performed on FNA cell blocks compared with surgical tissue blocks. 
      Cancer Cytopathol 2016;124:828-35. (c) 2016 American Cancer Society.
CI  - (c) 2016 American Cancer Society.
FAU - Vohra, Poonam
AU  - Vohra P
AD  - Department of Pathology, University of California at San Francisco, San 
      Francisco, California.
FAU - Buelow, Benjamin
AU  - Buelow B
AD  - Department of Pathology, University of California at San Francisco, San 
      Francisco, California.
FAU - Chen, Yunn-Yi
AU  - Chen YY
AD  - Department of Pathology, University of California at San Francisco, San 
      Francisco, California.
FAU - Serrano, Maria
AU  - Serrano M
AD  - Department of Pathology, Kaiser Permanente Medical Center, San Francisco.
FAU - Vohra, Manjiv Singh
AU  - Vohra MS
AD  - ECC, Burlingame, California.
FAU - Berry, Anna
AU  - Berry A
AD  - Cell Netix Pathology and Laboratories, Swedish Cancer Institute.
FAU - Ljung, Britt-Marie
AU  - Ljung BM
AD  - Department of Pathology, University of California at San Francisco, San 
      Francisco, California.
LA  - eng
PT  - Journal Article
DEP - 20160617
PL  - United States
TA  - Cancer Cytopathol
JT  - Cancer cytopathology
JID - 101499453
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - *Biomarkers, Tumor
MH  - *Biopsy, Fine-Needle/methods
MH  - Breast Neoplasms/*diagnosis/*metabolism
MH  - Female
MH  - Gene Amplification
MH  - Gene Expression
MH  - Humans
MH  - *Immunohistochemistry/methods
MH  - In Situ Hybridization, Fluorescence
MH  - Prognosis
MH  - Receptor, ErbB-2/genetics/*metabolism
MH  - Receptors, Estrogen/genetics/*metabolism
MH  - Receptors, Progesterone/genetics/*metabolism
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
OTO - NOTNLM
OT  - breast cancer
OT  - estrogen receptor (ER)
OT  - fluorescence in situ hybridization (FISH)
OT  - human epidermal growth factor receptor 2 (HER2)
OT  - immunohistochemistry
OT  - progesterone receptor (PR)
EDAT- 2016/06/18 06:00
MHDA- 2017/06/01 06:00
CRDT- 2016/06/18 06:00
PHST- 2016/03/02 00:00 [received]
PHST- 2016/03/24 00:00 [revised]
PHST- 2016/04/19 00:00 [accepted]
PHST- 2016/06/18 06:00 [pubmed]
PHST- 2017/06/01 06:00 [medline]
PHST- 2016/06/18 06:00 [entrez]
AID - 10.1002/cncy.21745 [doi]
PST - ppublish
SO  - Cancer Cytopathol. 2016 Nov;124(11):828-835. doi: 10.1002/cncy.21745. Epub 2016 
      Jun 17.